- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
59 result(s) found for: Nonsmall Cell Lung Cancer Stage III AND Pemetrexed.
Displaying page 2 of 3.
| EudraCT Number: 2021-006044-27 | Sponsor Protocol Number: IFCT-2103 | Start Date*: 2022-02-10 | |||||||||||
| Sponsor Name:IFCT | |||||||||||||
| Full Title: A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pe... | |||||||||||||
| Medical condition: Advanced Non Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001792-39 | Sponsor Protocol Number: G300505 | Start Date*: 2012-01-04 | |||||||||||||||||||||
| Sponsor Name:GTx, Inc. | |||||||||||||||||||||||
| Full Title: Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients with Non-Small Cell Lung Cancer on First Line Platinum Plus a Non-Taxane Chemoth... | |||||||||||||||||||||||
| Medical condition: Cachexia, muscle wasting in patients with Non-Small Cell Lung Cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: PL (Completed) HU (Completed) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2007-007639-17 | Sponsor Protocol Number: UCL/07/158 | Start Date*: 2008-09-24 | ||||||||||||||||
| Sponsor Name:University College London | ||||||||||||||||||
| Full Title: A multicentre, randomised, phase III trial of platinum-based chemotherapy versus non-platinum chemotherapy, after ERCC1 stratification, in patients with advanced/metastatic non-small cell lung cancer | ||||||||||||||||||
| Medical condition: Non-small cell lung cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2021-005487-22 | Sponsor Protocol Number: A2A-005 | Start Date*: 2022-12-21 | |||||||||||
| Sponsor Name:iTeos Belgium SA | |||||||||||||
| Full Title: A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell ... | |||||||||||||
| Medical condition: Nonsquamous non-small cell lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) PL (Completed) DE (Ongoing) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2011-001084-42 | Sponsor Protocol Number: 9090-08 | Start Date*: 2011-07-15 | ||||||||||||||||
| Sponsor Name:Synta Pharmaceuticals Corp. | ||||||||||||||||||
| Full Title: A Randomized, Phase IIb/III Study of Ganetespib (STA-9090) in Combination with Docetaxel versus Docetaxel alone in Subjects with Stage IIIb or IV Non-Small Cell Lung Cancer | ||||||||||||||||||
| Medical condition: Non-Small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: CZ (Completed) DE (Prematurely Ended) GB (Prematurely Ended) HU (Completed) ES (Prematurely Ended) BE (Prematurely Ended) PL (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2018-001006-28 | Sponsor Protocol Number: 20170770 | Start Date*: 2019-09-13 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: PROCLAIM: A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of No... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: non-small cell lung cancer (NSCLC), ovarian cancer, or breast cancer | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GR (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) AT (Completed) HU (Completed) ES (Ongoing) RO (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2005-005535-10 | Sponsor Protocol Number: H3E-MC-JMHX(c) | Start Date*: 2007-01-22 | |||||||||||
| Sponsor Name:Eli Lilly and Company Limited | |||||||||||||
| Full Title: A Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid | |||||||||||||
| Medical condition: either (1) relapsed, advanced (Stage III or IV) NSCLC or (2) malignant pleural or peritoneal mesothelioma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2014-003083-21 | Sponsor Protocol Number: GO29431 | Start Date*: 2015-08-20 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH A PLATINUM AGENT (CISPLATIN OR CARBOPLATIN) IN COMBINATION WITH EITHER PEMETREXED OR GEMCITABINE FOR ... | |||||||||||||
| Medical condition: Stage IV Non-Squamous or Squamous Non−Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) CZ (Prematurely Ended) ES (Ongoing) GR (Completed) FR (Completed) PL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2013-004303-39 | Sponsor Protocol Number: NVALT17 | Start Date*: 2014-04-11 | |||||||||||
| Sponsor Name:Stichting NVALT Studies | |||||||||||||
| Full Title: A randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed as first-line therapy for advanced EGFR mutated non-small-cell lung cancer. The NVALT17 study | |||||||||||||
| Medical condition: Advanced non-small cell lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) BE (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2019-003969-18 | Sponsor Protocol Number: D5162C00042 | Start Date*: 2021-07-21 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with ... | |||||||||||||
| Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Trial now transitioned) AT (Completed) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-001375-21 | Sponsor Protocol Number: D419AC00002 | Start Date*: 2018-06-28 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients with PD-L1-High Express... | |||||||||||||
| Medical condition: First line patients with Advanced Non Small-Cell Lung Cancer (NSCLC) with PD-L1 positive membrane expression in tumoral tissue and lacking activating epdermal growth factor receptor (EGFR) mutation... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-001279-39 | Sponsor Protocol Number: D419AC00001 | Start Date*: 2015-09-03 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in Fi... | |||||||||||||
| Medical condition: Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) in treatment naiive patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild type tumour pathology. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) DE (Completed) BE (Completed) HU (Completed) ES (Ongoing) FR (Completed) IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-008372-13 | Sponsor Protocol Number: LOC/08-09ESOGIA | Start Date*: 2009-04-02 | ||||||||||||||||
| Sponsor Name:CHU de Rennes [...] | ||||||||||||||||||
| Full Title: Etude de phase III randomisée, ouverte, multicentrique comparant chez des sujets âgés de plus de 70 ans atteints de cancer bronchique non à petites cellules de stade IV ou IIIb (T4 plèvre ou périca... | ||||||||||||||||||
| Medical condition: Il n’existe pas à ce jour d’étude validant une échelle gériatrique permettant de définir les populations susceptibles de bénéficier d’une chimiothérapie et à fortiori du type de chimiothérapie. Ce... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) ES (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2020-000556-35 | Sponsor Protocol Number: D910LC00001 | Start Date*: 2020-12-01 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected ... | |||||||||||||
| Medical condition: Completely Resected Stage II-III NSCLC | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) NL (Prematurely Ended) DK (Prematurely Ended) BG (Completed) HU (Prematurely Ended) DE (Completed) BE (Completed) SE (Prematurely Ended) PL (Completed) CZ (Completed) GR (Completed) IT (Prematurely Ended) FR (Completed) RO (Ongoing) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002997-29 | Sponsor Protocol Number: D9106C00001 | Start Date*: 2019-01-07 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lun... | |||||||||||||
| Medical condition: Patients with resectable Non-small Cell Lung Cancer (Stage IIA to IIIB; either squamous or non-squamous) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: HU (Trial now transitioned) AT (Trial now transitioned) BG (Completed) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-002382-19 | Sponsor Protocol Number: PDC-LUNG-101 | Start Date*: 2019-06-13 | |||||||||||
| Sponsor Name:PDC*line Pharma SAS | |||||||||||||
| Full Title: An open-label, dose-escalation, phase I/II study to assess the safety, the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic cancer vaccine, PDC*lung01, asso... | |||||||||||||
| Medical condition: Non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-003183-36 | Sponsor Protocol Number: OSE2101C301 | Start Date*: 2015-12-29 | |||||||||||
| Sponsor Name:OSE Immunotherapeutics | |||||||||||||
| Full Title: A randomized parallel group phase III trial of OSE 2101 as 2nd or 3rd line compared with standard treatment (docetaxel or pemetrexed) in HLA-A2 positive patients with locally advanced (IIIB) unsuit... | |||||||||||||
| Medical condition: Non-Small-Cell Lung Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) HU (Completed) DE (Completed) ES (Ongoing) PL (Completed) SI (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2017-000920-81 | Sponsor Protocol Number: D419MC00004 | Start Date*: 2017-08-30 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy fo... | |||||||||||||
| Medical condition: First-line patients with metastatistic non-small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fus... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BG (Completed) HU (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2014-003205-15 | Sponsor Protocol Number: GO29527 | Start Date*: 2015-11-30 | |||||||||||
| Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
| Full Title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHE... | |||||||||||||
| Medical condition: NON−SMALL CELL LUNG CANCER | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-002197-21 | Sponsor Protocol Number: D419AC00003 | Start Date*: 2016-02-19 | |||||||||||
| Sponsor Name:AstraZeneca AB | |||||||||||||
| Full Title: A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Pa... | |||||||||||||
| Medical condition: Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) in treatment naive patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild type tumour pathology. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BG (Completed) GB (GB - no longer in EU/EEA) FI (Completed) SE (Completed) PL (Completed) PT (Completed) GR (Completed) DK (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
